

Supplementary Table 1: Mean levels of urine biomarkers over time in responders and non-responders (complements Figure 1).

Urine biomarker†	Month post biopsy	WITHOUT adjustment of biomarker levels for urine creatinine levels			WITH adjustment of biomarker levels for urine creatinine levels		
		Non-response		p	Non-response		p
		Mean ± SE	Mean ± SE		Mean ± SE	Mean ± SE	
NGAL	0	3.77 ± 0.22	3.20 ± 0.23	0.079	-0.82 ± 0.23	-1.41 ± 0.24	0.079
	3	3.17 ± 0.32	2.73 ± 0.34	0.346	-1.63 ± 0.33	-1.85 ± 0.34	0.647
	6	3.41 ± 0.24	2.39 ± 0.25	0.004	-1.35 ± 0.24	-2.37 ± 0.26	0.005
	9	3.09 ± 0.34	3.29 ± 0.35	0.682	-1.45 ± 0.34	-1.65 ± 0.34	0.686
	12	3.58 ± 0.28	2.54 ± 0.31	0.014	-1.35 ± 0.28	-2.40 ± 0.30	0.013
Ceruloplasmin	0	9.76 ± 0.29	8.58 ± 0.30	0.006	5.07 ± 0.32	3.96 ± 0.32	0.015
	3	9.16 ± 0.42	7.00 ± 0.47	0.001	4.29 ± 0.48	2.55 ± 0.49	0.013
	6	9.44 ± 0.32	7.31 ± 0.33	0.000	4.58 ± 0.33	2.63 ± 0.34	0.000
	9	8.71 ± 0.47	7.62 ± 0.49	0.112	3.81 ± 0.50	2.63 ± 0.49	0.093
	12	8.13 ± 0.36	7.23 ± 0.43	0.114	3.21 ± 0.40	2.33 ± 0.43	0.137
KIM1	0	7.37 ± 0.22	7.10 ± 0.23	0.402	2.65 ± 0.20	2.46 ± 0.20	0.510
	3	6.90 ± 0.31	5.71 ± 0.33	0.010	2.03 ± 0.29	1.02 ± 0.31	0.019
	6	7.09 ± 0.23	5.75 ± 0.25	0.000	2.21 ± 0.21	1.03 ± 0.22	0.000
	9	6.85 ± 0.34	5.86 ± 0.36	0.049	2.08 ± 0.31	0.91 ± 0.31	0.009
	12	6.84 ± 0.27	6.50 ± 0.31	0.421	2.11 ± 0.25	1.63 ± 0.27	0.201
MCP1	0	6.87 ± 0.21	6.28 ± 0.22	0.057	2.14 ± 0.18	1.55 ± 0.18	0.022
	3	6.38 ± 0.32	5.25 ± 0.33	0.016	1.34 ± 0.27	0.59 ± 0.28	0.053
	6	6.51 ± 0.24	5.27 ± 0.24	0.000	1.69 ± 0.19	0.50 ± 0.20	0.000
	9	6.08 ± 0.36	5.60 ± 0.36	0.347	1.28 ± 0.29	0.63 ± 0.28	0.112
	12	5.98 ± 0.27	5.53 ± 0.33	0.289	1.20 ± 0.23	0.64 ± 0.26	0.108
Adiponectin	0	2.67 ± 0.40	2.74 ± 0.49	0.914	-2.30 ± 0.43	-1.84 ± 0.58	0.528
	3	2.30 ± 0.58	0.09 ± 0.55	0.008	-2.46 ± 0.61	-5.22 ± 0.58	0.002
	6	2.32 ± 0.44	-0.49 ± 0.42	0.000	-2.84 ± 0.46	-5.38 ± 0.42	0.000
	9	2.40 ± 0.66	-0.23 ± 0.58	0.004	-2.39 ± 0.65	-5.05 ± 0.58	0.003
	12	0.80 ± 0.58	0.10 ± 0.62	0.410	-4.50 ± 0.57	-5.39 ± 0.69	0.327
Hemopexin	0	8.10 ± 0.25	7.82 ± 0.26	0.443	3.36 ± 0.27	3.09 ± 0.28	0.490
	3	7.67 ± 0.39	6.53 ± 0.42	0.049	2.87 ± 0.40	1.85 ± 0.44	0.090
	6	8.00 ± 0.27	6.57 ± 0.28	0.000	3.23 ± 0.29	1.81 ± 0.30	0.001
	9	7.08 ± 0.42	6.90 ± 0.42	0.763	2.44 ± 0.44	1.96 ± 0.44	0.448
	12	7.63 ± 0.33	6.73 ± 0.36	0.069	2.67 ± 0.35	1.90 ± 0.38	0.141
Transferrin	0	2.12 ± 0.32	0.93 ± 0.34	0.012	-2.41 ± 0.30	-3.78 ± 0.31	0.002
	3	2.06 ± 0.47	-1.43 ± 0.76	0.000	-2.58 ± 0.45	-5.83 ± 0.70	0.000
	6	1.77 ± 0.36	-0.72 ± 0.54	0.000	-3.01 ± 0.33	-5.42 ± 0.49	0.000
	9	1.69 ± 0.56	-0.95 ± 0.69	0.004	-3.12 ± 0.52	-6.18 ± 0.64	0.000
	12	1.15 ± 0.44	-0.22 ± 0.54	0.052	-3.74 ± 0.40	-5.00 ± 0.49	0.052
AGP	0	11.44 ± 0.36	10.24 ± 0.38	0.023	6.84 ± 0.36	5.60 ± 0.38	0.021
	3	11.29 ± 0.54	8.12 ± 0.59	0.000	6.52 ± 0.53	3.40 ± 0.57	0.000
	6	10.67 ± 0.40	7.38 ± 0.40	0.000	5.83 ± 0.39	2.69 ± 0.40	0.000
	9	10.34 ± 0.58	7.89 ± 0.59	0.004	5.67 ± 0.57	2.89 ± 0.57	0.001
	12	10.08 ± 0.47	7.95 ± 0.51	0.003	5.17 ± 0.46	3.06 ± 0.49	0.002
VDBP	0	6.65 ± 0.31	5.65 ± 0.32	0.027	2.10 ± 0.31	0.97 ± 0.32	0.012
	3	5.88 ± 0.47	3.65 ± 0.51	0.002	1.09 ± 0.44	-1.05 ± 0.47	0.001
	6	5.58 ± 0.34	3.87 ± 0.35	0.001	0.76 ± 0.32	-0.87 ± 0.34	0.001
	9	5.55 ± 0.51	3.73 ± 0.51	0.012	0.89 ± 0.47	-1.21 ± 0.47	0.002
	12	5.12 ± 0.40	3.88 ± 0.44	0.041	0.17 ± 0.39	-1.02 ± 0.41	0.038


MALB‡	0	6.00 ± 0.36	5.46 ± 0.37	0.297	1.54 ± 0.34	0.80 ± 0.34	0.122
	3	5.86 ± 0.56	3.79 ± 0.58	0.012	0.90 ± 0.49	-0.90 ± 0.51	0.013
	6	5.19 ± 0.40	3.43 ± 0.40	0.002	0.90 ± 0.36	-1.21 ± 0.36	0.000
	9	5.44 ± 0.61	2.50 ± 0.61	0.001	0.61 ± 0.53	-2.49 ± 0.53	0.000
	12	5.27 ± 0.46	3.61 ± 0.54	0.021	0.30 ± 0.42	-1.25 ± 0.47	0.016

Supplementary Table 1 legend: †: Values in cells are mean ± SE of (nature) log transformed Biomarkers in the table. ‡: MALB = microalbumin with adjustment of creatinine is equivalent to MALB/creatinine ratio in the table.

Supplementary Table 2: Mean biomarker levels by response over time.

Biomarker	Month	ISN/PRS Class 3 and 4			ISN/PRS CLASS 5		
		Non-responders Mean ± SE	Responders Mean ± SE	P-value	Non-responders Mean ± SE	Responders Mean ± SE	P-value
Adiponectin	0	11.42 ± 0.48	10.00 ± 0.48	0.042	9.75 ± 0.69	10.82 ± 0.78	0.312
Adiponectin	3	9.44 ± 1.11	7.82 ± 0.73	0.229	10.15 ± 0.81	6.80 ± 1.05	0.016
Adiponectin	6	9.56 ± 0.59	7.75 ± 0.51	0.025	9.77 ± 0.77	6.37 ± 0.88	0.006
Adiponectin	12	9.24 ± 0.65	8.15 ± 0.68	0.253	9.56 ± 0.87	8.50 ± 0.83	0.380
AGP	0	11.57 ± 0.49	9.50 ± 0.50	0.005	11.69 ± 0.63	11.75 ± 0.72	0.945
AGP	3	10.84 ± 1.15	7.23 ± 0.80	0.013	11.33 ± 0.66	9.78 ± 0.83	0.152
AGP	6	9.62 ± 0.61	6.97 ± 0.52	0.002	11.92 ± 0.63	8.42 ± 0.72	0.001
AGP	12	9.70 ± 0.67	7.04 ± 0.75	0.011	10.21 ± 0.69	9.02 ± 0.69	0.232
Ceruloplasmin	0	9.97 ± 0.38	8.29 ± 0.38	0.003	10.37 ± 0.57	9.37 ± 0.64	0.250
Ceruloplasmin	3	8.77 ± 0.70	6.62 ± 0.59	0.023	9.81 ± 0.66	7.73 ± 0.85	0.062
Ceruloplasmin	6	8.44 ± 0.46	6.92 ± 0.41	0.017	10.13 ± 0.63	8.10 ± 0.72	0.041
Ceruloplasmin	12	8.12 ± 0.48	7.19 ± 0.59	0.223	7.87 ± 0.71	7.39 ± 0.68	0.624
Cystatin-C	0	4.24 ± 0.35	3.89 ± 0.38	0.530	4.45 ± 0.30	4.11 ± 0.35	0.493
Cystatin-C	3	5.10 ± 0.85	3.46 ± 0.49	0.156	3.66 ± 0.31	3.49 ± 0.34	0.731
Cystatin-C	6	4.44 ± 0.42	3.40 ± 0.32	0.108	4.63 ± 0.26	3.95 ± 0.29	0.137
Cystatin-C	12	3.59 ± 0.49	3.44 ± 0.49	0.839	4.75 ± 0.41	3.56 ± 0.32	0.063
Hepcidin	0	3.99 ± 0.59	4.50 ± 0.72	0.594	5.41 ± 0.79	3.36 ± 0.88	0.102
Hepcidin	3	5.67 ± 1.77	5.77 ± 0.72	0.956	4.23 ± 0.72	3.01 ± 0.88	0.298
Hepcidin	6	3.21 ± 0.79	3.45 ± 0.56	0.803	4.15 ± 0.72	2.85 ± 0.72	0.218
Hepcidin	12	3.95 ± 0.88	3.34 ± 0.88	0.635	4.59 ± 1.01	3.99 ± 1.01	0.685
Hemopexin	0	7.74 ± 0.35	7.46 ± 0.36	0.573	8.85 ± 0.43	8.25 ± 0.49	0.361
Hemopexin	3	8.28 ± 0.86	6.35 ± 0.61	0.074	7.34 ± 0.49	6.79 ± 0.64	0.503
Hemopexin	6	7.16 ± 0.45	6.12 ± 0.37	0.080	8.53 ± 0.45	7.06 ± 0.52	0.041
Hemopexin	12	8.30 ± 0.50	6.24 ± 0.56	0.009	7.32 ± 0.52	7.02 ± 0.49	0.671
KIM-1	0	7.71 ± 0.28	6.87 ± 0.29	0.042	6.86 ± 0.40	6.99 ± 0.45	0.822
KIM-1	3	7.23 ± 0.58	5.41 ± 0.44	0.016	6.62 ± 0.46	5.71 ± 0.58	0.229
KIM-1	6	6.80 ± 0.34	5.29 ± 0.30	0.002	7.34 ± 0.43	5.97 ± 0.50	0.046
KIM-1	12	7.00 ± 0.37	6.70 ± 0.44	0.610	6.41 ± 0.45	6.15 ± 0.47	0.694
LFABP	0	3.10 ± 0.37	2.54 ± 0.41	0.332	2.95 ± 0.50	3.52 ± 0.48	0.425
LFABP	3	4.74 ± 1.17	1.28 ± 0.68	0.021	2.10 ± 0.48	1.63 ± 0.61	0.555
LFABP	6	1.76 ± 0.52	0.76 ± 0.39	0.146	3.25 ± 0.44	1.40 ± 0.53	0.017
LFABP	12	1.62 ± 0.59	0.94 ± 0.68	0.457	2.47 ± 0.53	1.07 ± 0.49	0.072
LPGDS	0	5.87 ± 0.43	5.09 ± 0.39	0.206	7.13 ± 0.65	4.97 ± 0.80	0.000
LPGDS	3	5.37 ± 0.68	4.31 ± 0.69	0.291	6.02 ± 0.65	5.46 ± 1.13	0.000
LPGDS	6	4.14 ± 0.49	4.16 ± 0.49	0.979	4.96 ± 0.65	4.60 ± 1.13	0.000
LPGDS	12	5.15 ± 0.54	5.21 ± 0.69	0.945	5.83 ± 0.80	5.02 ± 0.80	0.000
MCP-1	0	7.25 ± 0.30	5.92 ± 0.30	0.003	6.45 ± 0.39	6.27 ± 0.44	0.763
MCP-1	3	6.87 ± 0.62	4.96 ± 0.47	0.017	6.22 ± 0.46	5.37 ± 0.60	0.271
MCP-1	6	6.27 ± 0.36	5.01 ± 0.32	0.011	6.93 ± 0.44	5.21 ± 0.50	0.014
MCP-1	12	6.11 ± 0.38	5.60 ± 0.50	0.416	5.92 ± 0.46	5.30 ± 0.50	0.373
NGAL	0	3.87 ± 0.29	3.15 ± 0.29	0.087	4.09 ± 0.36	2.99 ± 0.41	0.049
NGAL	3	3.36 ± 0.57	2.75 ± 0.47	0.412	3.35 ± 0.40	2.54 ± 0.53	0.227
NGAL	6	3.41 ± 0.33	1.96 ± 0.31	0.002	3.62 ± 0.38	2.46 ± 0.44	0.052
NGAL	12	3.71 ± 0.37	2.23 ± 0.44	0.013	3.32 ± 0.43	2.42 ± 0.41	0.138
Osteopontin	0	4.43 ± 0.37	4.02 ± 0.44	0.488	5.05 ± 0.44	5.03 ± 0.52	0.979
Osteopontin	3	5.66 ± 1.51	4.67 ± 0.64	0.552	4.76 ± 0.48	5.31 ± 0.58	0.472
Osteopontin	6	4.01 ± 0.49	4.12 ± 0.40	0.865	4.90 ± 0.41	5.06 ± 0.48	0.802
Osteopontin	12	3.68 ± 0.51	4.05 ± 0.64	0.658	4.26 ± 0.52	4.68 ± 0.52	0.568
Transferrin	0	8.96 ± 0.40	7.40 ± 0.40	0.012	9.58 ± 0.65	8.46 ± 0.70	0.253
Transferrin	3	7.85 ± 0.80	5.03 ± 0.92	0.030	9.12 ± 0.70	6.71 ± 1.71	0.208
Transferrin	6	7.59 ± 0.53	6.22 ± 0.60	0.102	9.10 ± 0.61	6.39 ± 1.21	0.060
Transferrin	12	8.40 ± 0.65	6.96 ± 0.79	0.172	7.94 ± 0.70	6.57 ± 0.77	0.202
TGF-β	0	3.88 ± 0.30	2.40 ± 0.29	0.001	3.99 ± 0.38	2.95 ± 0.42	0.078
TGF-β	3	3.21 ± 0.69	1.96 ± 0.49	0.142	2.93 ± 0.49	1.82 ± 0.60	0.162
TGF-β	6	2.40 ± 0.36	1.86 ± 0.30	0.251	3.21 ± 0.42	1.98 ± 0.49	0.067
TGF-β	12	2.58 ± 0.40	2.16 ± 0.45	0.488	2.48 ± 0.49	2.00 ± 0.45	0.479
VDBP	0	6.47 ± 0.40	5.04 ± 0.42	0.018	6.76 ± 0.63	6.57 ± 0.68	0.844
VDBP	3	5.37 ± 0.94	3.27 ± 0.66	0.073	6.42 ± 0.67	4.35 ± 0.86	0.067
VDBP	6	4.49 ± 0.50	3.38 ± 0.43	0.100	6.46 ± 0.63	4.40 ± 0.73	0.040
VDBP	12	5.02 ± 0.55	3.62 ± 0.61	0.096	5.13 ± 0.71	4.09 ± 0.68	0.298

Supplementary Table 2 legend: †Values in cells are (natural log) transformed and not corrected by urine creatinine.



Supplementary Table 3: Accuracy of the biomarkers to predict response at 6 months (complements Figure 3B).

Biomarker	Month 0	Month 3	Month 6
	AUC (95% CI)	AUC (95% CI)	AUC (95% CI)
AGP	0.63 (0.49, 0.77)	0.98 (0.94, 1.00)	0.87 (0.77, 0.97)
Adiponectin	0.51 (0.30, 0.72)	0.88 (0.71, 1.00)	0.93 (0.84, 1.00)
Ceruloplasmin	0.69 (0.56, 0.82)	0.83 (0.68, 0.99)	0.79 (0.66, 0.92)
Cystatin-C	0.61 (0.35, 0.88)	0.79 (0.52, 1.00)	0.78 (0.60, 0.96)
Hepcidin	0.62 (0.47, 0.77)	0.62 (0.39, 0.85)	0.58 (0.42, 0.74)
Hemopexin	0.60 (0.45, 0.74)	0.80 (0.60, 1.00)	0.75 (0.61, 0.88)
KIM1	0.58 (0.44, 0.73)	0.81 (0.63, 0.99)	0.73 (0.59, 0.87)
LFABP	0.47 (0.24, 0.69)	0.80 (0.53, 1.00)	0.84 (0.68, 1.00)
LPGDS	0.74 (0.55, 0.92)	0.75 (0.33, 1.00)	0.61 (0.36, 0.86)
MCP1	0.64 (0.50, 0.78)	0.81 (0.64, 0.98)	0.75 (0.61, 0.89)
NGAL	0.62 (0.48, 0.76)	0.67 (0.44, 0.89)	0.73 (0.60, 0.87)
Osteopontin	0.55 (0.40, 0.70)	0.60 (0.36, 0.85)	0.55 (0.39, 0.71)
Transferrin	0.67 (0.53, 0.82)	0.95 (0.86, 1.00)	0.86 (0.73, 0.99)
TGF-β	0.73 (0.60, 0.86)	0.82 (0.66, 0.99)	0.68 (0.53, 0.82)
VDBP	0.63 (0.49, 0.78)	0.90 (0.76, 1.00)	0.78 (0.66, 0.91)
Combined RAIL biomarkers	0.76 (0.52, 1.00)	0.92 (0.90, 1.00)†	0.91 (0.87, 1.00)

Supplementary Table 4: Assessment of moderations (or interactions) of race and sex in affecting associations of urine biomarkers vs. response.

Dependent variables	Race x Response Interaction					Sex x Response Interaction				
	Month=0	Month=3	Month=6	Month=9	Month=12	Month=0	Month=3	Month=6	Month=9	Month=12
	P-value	P-value	P-value	P-value	P-value	P-value	P-value	P-value	P-value	P-value
NGAL	0.588	0.853	0.682	0.981	0.614	0.768	0.316	0.379	0.775	0.338
CP	0.545	0.659	0.866	0.812	0.510	0.039	0.732	0.237	0.993	0.930
KIM-1	0.285	0.925	0.918	0.477	0.007	0.745	0.899	0.966	0.573	0.874
MCP-1	0.133	0.465	0.915	0.513	0.331	0.171	0.333	0.917	0.404	0.577
Osteopontin	0.001	0.599	0.675	0.149	0.986	0.145	0.742	0.858	0.590	0.860
AGP	0.125	0.818	0.124	0.883	0.792	0.395	0.150	0.430	0.182	0.242
TGF-β	0.932	0.881	0.464	0.942	0.224	0.807		0.267	0.299	0.642
LFABP	0.163	0.493	0.058	0.781	0.278	0.513		0.448	0.655	0.474
Adiponectin	0.155	0.175	0.830	0.512	0.657	0.872	0.774	0.185	0.363	0.935
Hepcidin	0.281	0.987	0.244	0.906	0.943	0.842	0.866	0.163	0.747	0.380
Transferrin	0.723	0.809	0.565	1.000	0.754	0.399	0.057	0.360		0.211
VDBP	0.068	0.793	0.807	0.877	0.704	0.597	0.040	0.401	0.746	0.771
Hemopexin	0.249	0.432	0.834	0.888	0.174	0.974	0.021	0.292	0.785	0.581
Cystatin-C	0.988	0.140	0.487	0.152	0.404	0.528		0.667	0.695	
LPGDS	0.251	0.340	0.539		0.418	0.543	0.022	0.231		0.603

Supplementary Table 5: Spearman correlations for non-adjusted urine biomarker levels with extra-renal disease activity as measured by the SLEDAI.

Month	0	3	6	12
NGAL	0.38*	0.32	-0.14	0.17
CP	0.05	0.26	0.25	0.37
KIM-1	0.13	0.17	0.02	0.15
MCP-1	0.12	0.17	0.08	0.00
Osteopontin	0.00	0.08	0.23	-0.05
AGP	0.13	0.23	0.02	0.15
TGF-β	0.29*	0.59**	0.08	0.40*
LFABP	0.10	0.39	0.12	0.30
Adiponectin	0.25	0.13	-0.03	0.14
Hepcidin	0.06	-0.34	-0.30	-0.35
Transferrin	0.06	0.35	0.31	0.33
VDBP	0.15	0.19	0.04	0.03
Hemopexin	0.07	0.06	0.09	-0.07
CYSTATINC	0.10	0.47	0.06	-0.16
LPGDS	0.65**	0.01	0.04	-0.22

Supplementary Table 6: Assessment of moderations (or interactions) of using ACE/ARB in affecting the associations of urine biomarkers vs. response.

Biomarker	p-values				
	Month=0	Month=3	Month=6	Month=9	Month=12
NGAL	0.310	0.286	0.633	0.468	0.816
CP	0.530	0.323	0.172	0.963	0.973
KIM-1	0.664	0.498	0.358	0.459	0.536
MCP-1	0.871	0.463	0.451	0.375	0.649
EPCR	0.338	0.374	0.649	0.487	0.914
AGP	0.427	0.052	0.041	0.761	0.846
TGF-β	0.173	0.550	0.234	0.757	0.077
LFABP	0.128	0.436	0.574	0.414	0.644
Adiponectin	0.623	0.192	0.220	0.944	0.973
Hepcidin	0.882	0.373	0.744	0.339	0.900
Transferrin	0.392	0.290	0.208	0.656	0.096
VDBP	0.202	0.241	0.833	0.662	0.989
Hemopexin	0.261	0.127	0.274	0.902	0.371
Cystatin-C	0.421	0.095	0.633	0.627	0.713
LPGDS	0.687	0.513	0.345	Not available	0.813

Supplementary Table 7: Changes of non-adjusted biomarkers (follow up vs. baseline) with CTX or MMF therapy*.


Biomarker	Adiponectin				AGP				Ceruloplasmin				Cystatin-C				Hemopexin				
Follow Up Month	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	
CTX	Mean ± SE	-1.08 ± 0.92	-2.14 ± 0.67	-0.20 ± 1.13	-2.40 ± 0.85	-2.07 ± 0.74	-2.49 ± 0.49	-1.90 ± 0.98	-2.83 ± 0.62	-1.52 ± 0.58	-1.52 ± 0.40	-1.13 ± 0.75	-1.67 ± 0.50	0.07 ± 0.41	0.10 ± 0.32	1.46 ± 0.52	0.37 ± 0.37	-0.77 ± 0.56	-0.85 ± 0.38	-0.95 ± 0.75	-0.66 ± 0.48
	p	0.249	0.002	0.857	0.007	0.006	0.000	0.055	0.000	0.011	0.000	0.136	0.001	0.864	0.758	0.012	0.325	0.176	0.028	0.209	0.170
MMF	Mean ± SE	-2.12 ± 0.77	-1.56 ± 0.61	-1.88 ± 0.75	-2.11 ± 0.72	-0.84 ± 0.66	-1.31 ± 0.47	-1.69 ± 0.61	-1.42 ± 0.52	-0.77 ± 0.49	-0.09 ± 0.39	-1.37 ± 0.50	-1.62 ± 0.42	-0.91 ± 0.40	-0.32 ± 0.26	-0.76 ± 0.41	-0.53 ± 0.33	-0.76 ± 0.49	-0.31 ± 0.36	-1.29 ± 0.46	-0.74 ± 0.40
	p	0.009	0.015	0.016	0.005	0.206	0.007	0.007	0.008	0.123	0.822	0.008	0.000	0.039	0.230	0.081	0.124	0.125	0.390	0.006	0.066
Biomarker	Hepcidin				KIM-1				LFABP				LPGDS				MCP-1				
Follow Up Month	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	
CTX	Mean ± SE	-2.40 ± 1.20	-1.01 ± 0.81	-2.14 ± 1.61	0.12 ± 1.03	-1.13 ± 0.43	-1.33 ± 0.31	-0.41 ± 0.55	-0.69 ± 0.37	-0.99 ± 0.63	-1.00 ± 0.50	-0.16 ± 0.77	-0.73 ± 0.59	-1.32 ± 0.64	-1.50 ± 0.38	-1.25 ± 1.04	-0.81 ± 0.52	-1.05 ± 0.44	-1.09 ± 0.31	-0.32 ± 0.57	-0.85 ± 0.41
	p	0.049	0.217	0.189	0.909	0.010	0.000	0.458	0.068	0.125	0.051	0.835	0.224	0.050	0.001	0.242	0.135	0.020	0.001	0.574	0.040
MMF	Mean ± SE	2.08 ± 1.01	-2.24 ± 0.77	-2.40 ± 0.97	-0.31 ± 0.83	-0.69 ± 0.37	-0.21 ± 0.29	-0.99 ± 0.37	-0.55 ± 0.32	-1.14 ± 0.61	-1.50 ± 0.41	-2.17 ± 0.51	-2.14 ± 0.46	0.04 ± 0.44	0.21 ± 0.44	-0.93 ± 0.60	-0.25 ± 0.46	-0.57 ± 0.37	-0.29 ± 0.30	-0.97 ± 0.39	-0.82 ± 0.32
	p	0.043	0.004	0.015	0.708	0.063	0.483	0.009	0.085	0.070	0.001	0.000	0.000	0.937	0.643	0.134	0.588	0.131	0.341	0.015	0.011
Biomarker	NGAL				TGF-β				Transferrin				VDBP								
Follow Up Month	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	3	6	9	12	
CTX	Mean ± SE	-0.86 ± 0.42	-0.69 ± 0.29	-0.47 ± 0.54	-0.39 ± 0.36	-0.62 ± 0.49	-1.08 ± 0.32	-0.18 ± 0.56	-0.96 ± 0.40	-1.18 ± 0.80	-1.74 ± 0.51	-1.23 ± 1.03	-1.54 ± 0.61	-2.13 ± 0.63	-2.21 ± 0.42	-0.80 ± 0.84	-2.01 ± 0.53				
	p	0.042	0.018	0.386	0.274	0.205	0.001	0.743	0.017	0.145	0.001	0.237	0.015	0.001	0.000	0.345	0.000				
MMF	Mean ± SE	-0.43 ± 0.36	-0.35 ± 0.28	-0.32 ± 0.36	-0.28 ± 0.31	-0.76 ± 0.38	-0.45 ± 0.30	-1.33 ± 0.38	-0.95 ± 0.33	-0.62 ± 0.60	0.08 ± 0.50	-0.92 ± 0.64	-1.09 ± 0.52	-0.78 ± 0.57	-0.64 ± 0.41	-1.55 ± 0.52	-1.49 ± 0.44				
	p	0.237	0.210	0.372	0.359	0.052	0.137	0.001	0.005	0.307	0.876	0.156	0.038	0.175	0.124	0.004	0.001				
RAIL biomarkers																					

*Osteopontin is omitted due to non-responsiveness with LN course.


P > 0.1



0.005 ≤ P < 0.05



0.05 < P ≤ 0.1



P < 0.005

